Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
181 hedge funds and large institutions have $2.69B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 71 increasing their positions, 55 reducing their positions, and 31 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 55
7% less funds holding
Funds holding: 194 → 181 (-13)
28% less capital invested
Capital invested by funds: $3.75B → $2.69B (-$1.07B)
39% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 31
58% less call options, than puts
Call options by funds: $39.3M | Put options by funds: $94.7M
71% less funds holding in top 10
Funds holding in top 10: 7 → 2 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$73.7M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$25.8M |
| 3 |
Goldman Sachs
New York
|
+$13.5M |
| 4 |
Morgan Stanley
New York
|
+$11.2M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$9.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$42.6M |
| 2 |
DM
Deerfield Management
New York
|
-$42.5M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$11.7M |
| 4 |
SC
Samlyn Capital
New York
|
-$11.1M |
| 5 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$10.1M |
RETA Hedge Fund Activity: Q3 2021 in Review
181 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2021, worth a combined $2.69B — down 28% from $3.75B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of RETA and 19 opened new positions — a net loss of 12 holders — while 55 trimmed existing stakes and 71 added.
The largest buyer was Invesco, adding an estimated $73.7M. The largest seller was Franklin Resources, cutting an estimated $42.6M.
- 181 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2021, down from 194 in Q2 2021.
- Funds reported $2.69B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2021, down 28% quarter-over-quarter.
- 19 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2021 and 31 closed out, a net change of -12 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q3 2021 was Invesco, an estimated $73.7M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2021 was Franklin Resources, an estimated $42.6M sold.
Based on aggregated 13F filings for Q3 2021.